Literature DB >> 16328972

Diminution in adenine nucleotide hydrolysis by platelets and serum from rats submitted to Walker 256 tumour.

Andréia Buffon1, Vanessa B Ribeiro, Alessandra S Schanoski, João J F Sarkis.   

Abstract

Extracellular adenine nucleotide hydrolysis in the circulation is mediated by the action of an NTPDase (CD39, apyrase) and of a 5'-nucleotidase (CD73), presenting as a final product, adenosine. Among other properties described for adenine nucleotides, an anti-cancer activity is suggested, since ATP is considered a cytotoxic molecule in several tumour cell systems. Conversely, some studies demonstrate that adenosine presents a tumour-promoting activity. In this study, we evaluated the pattern of adenine nucleotide hydrolysis by serum and platelets from rats submitted to the Walker 256 tumour model. Extracellular adenine nucleotide hydrolysis by blood serum and platelets obtained from rats at, 6, 10 and 15 days after the subcutaneous Walker 256 tumour inoculation, was evaluated. Our results demonstrate a significant reduction in ATP, ADP and AMP hydrolysis in blood serum at 6, 10 and 15 days after tumour induction. In platelets, a significant reduction in ATP and AMP hydrolysis was observed at 10 and 15 days after tumour induction, while an inhibition of ADP hydrolysis was observed at all times studied. Based on these results, it is possible to suggest a physiologic protection mechanism against the tumoral process in circulation. The inhibition in nucleotide hydrolysis observed probably maintains ATP levels elevated (cytotoxic compound) and, at the same time, reduces the adenosine production (tumour-promoting molecule) in the circulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16328972     DOI: 10.1007/s11010-006-1029-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  46 in total

1.  Extracellular adenosine triphosphate affects neural cell adhesion molecule (NCAM)-mediated cell adhesion and neurite outgrowth.

Authors:  G Skladchikova; L C Ronn; V Berezin; E Bock
Journal:  J Neurosci Res       Date:  1999-07-15       Impact factor: 4.164

2.  A direct colorimetric assay for Ca2+ -stimulated ATPase activity.

Authors:  K M Chan; D Delfert; K D Junger
Journal:  Anal Biochem       Date:  1986-09       Impact factor: 3.365

3.  Walker carcinoma 256: a model for studies on tumor-induced anorexia and cachexia.

Authors:  A Guaitani; M Recchia; M Carli; M Rocchetti; I Bartosek; S Garattini
Journal:  Oncology       Date:  1982       Impact factor: 2.935

Review 4.  Potential therapeutic targets in the rapidly expanding field of purinergic signalling.

Authors:  G Burnstock
Journal:  Clin Med (Lond)       Date:  2002 Jan-Feb       Impact factor: 2.659

5.  Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells.

Authors:  E Barcz; E Sommer; P Janik; L Marianowski; E Skopinska-Rózewska
Journal:  Oncol Rep       Date:  2000 Nov-Dec       Impact factor: 3.906

6.  Adenosine suppresses alpha(4)beta(7) integrin-mediated adhesion of T lymphocytes to colon adenocarcinoma cells.

Authors:  Willena M MacKenzie; David W Hoskin; Jonathan Blay
Journal:  Exp Cell Res       Date:  2002-05-15       Impact factor: 3.905

7.  Identification and characterization of CD39/vascular ATP diphosphohydrolase.

Authors:  E Kaczmarek; K Koziak; J Sévigny; J B Siegel; J Anrather; A R Beaudoin; F H Bach; S C Robson
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

8.  Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas.

Authors:  K N Dzhandzhugazyan; A F Kirkin; P thor Straten; J Zeuthen
Journal:  FEBS Lett       Date:  1998-07-03       Impact factor: 4.124

9.  Extracellular ATP induces ion fluxes and inhibits growth of Friend erythroleukemia cells.

Authors:  S B Chahwala; L C Cantley
Journal:  J Biol Chem       Date:  1984-11-25       Impact factor: 5.157

10.  Variability and discontinuity of the pathognomonic systemic effects caused by Walker 256 tumor progression in rats.

Authors:  O Rettori; A N Vieira-Matos; Q S Tahin
Journal:  Tumori       Date:  1995 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.